Anthelmintic preparation for treating small cattle

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary medicine, particularly to anthelmintic preparations for treating small cattle and can be used for treatment and prevention of helminthic invasions accompanied by reduced immunobiological properties. The anthelmintic preparation for treating small cattle contains albendazole, 40% Echinacea tincture, 4% methylcellulose - 100 and sorbic acid and distilled water in the ratio as follows, wt %: albendazole 2.5-5.0; 40% Echinacea tincture 9-12; 4% methylcellulose-100 20-25; sorbic acid 0.5-1.0; distilled water - the rest.

EFFECT: higher effectiveness and lower toxicity of the preparation.

2 tbl, 4 ex

 

The technical field to which the invention relates.

The invention relates to veterinary medicine, in particular to anthelminthic drugs for the treatment of small cattle, and can be used for the treatment and prevention of worm infestation, accompanied by a decrease of immunobiological properties of the organism.

The LEVEL of TECHNOLOGY

Known anthelmintic agent "Azinoks plus", which includes active active ingredient praziquantel, nilverm and chlorpromazine. Excipients: lactose, calcium stearate and starch at a mass ratio of praziquantel:nilverm:chlorpromazine:lactose, calcium stearate and starch 1:0,625-0,875:0,0625-0,1:3,5:0,0375:7,375-9,625 (see patent Ru No. 2100022, IPC AC 31/00, publ. 27.12.1997 g).

The disadvantage of this tool is the reduction of immunobiological properties of the organism.

Known anthelmintic agent, including benzimidazolecarbamate, at the same time as the active substance it contains a complex of albendazole and copper, which is optionally included in microcapsule of cellulose acetate in a ratio of albendazole, copper sulphate and acetate 1:1:0,5 respectively as initial products for its receipt (see patent Ru No. 2195280, IPC AC 31/415, AK 31/47, AK 31/495, AK 9/127, OR 33/10, publ. 27.12.2002 g).

The disadvantage of this tool is the low efficiency of the treatment.

Investeerimisega albendazole with vitamin E (see Sidorkin, VA, tagaeva ANALYSIS of the Efficacy of albendazole for oral administration against Dicrocoelium Lanceatum. - Mat. Scient. Proc. "Theory and practice of combating parasitic diseases". - VIP:M. 2006).

The disadvantage of this drug is rapid deposition of the active substance on the bottom of the bottle, which causes inconvenience in use of the drug experts and additional application of Immunostimulants.

DISCLOSURE of INVENTIONS

The task of the invention is to develop a deworming drug for the treatment of small ruminants with high immunostimulating properties, which helps to intensify the treatment and prevention of a number of worm infestations, accompanied by a decrease of immunobiological properties of the organism, as well as cheaper, more efficient product.

The technical result that can be achieved using the present invention is to increase immunostimulatory properties of the body of small cattle, efficacy and low cost.

The technical result is achieved by anthelminthic drug for the treatment of small cattle, including albendazole and distilled water, it additionally contains the tincture of Echinacea 40%solution of methylcellulose-100(MC-100) 4%and erbenova acid in the following ratio in wt.%:

Albendazole2,5-5,0
Tincture of Echinacea 40%9-12
The solution MC-100 4%20-25
Sorbic acid0,5-1,0
Distilled waterRest

Thus, the technical result is an increase of immunostimulatory properties of the organism is achieved by the inclusion of tinctures of Echinacea purpurea (Echinacea purpurea), which according to the instruction for medical use of drugs contain active substances that enhance the natural defenses of the body and acting as a nonspecific stimulant, increasing the number of leukocytes (granulocytes), and activating phagocytosis. That according to Daugalieva AH: "the protection of animals from worm infestation are important cells capable of phagocytosis. Particular importance is attached to the state of cellular enzymes and especially the Alp level as indicator protective functions of granulocytes. There is a natural increase in the level of this enzyme in inflammatory processes. The reaction of phagocytosis, taking into account perevarivatei phagocytes - reliable test that reflects the state of the immune system of an organism at different worm" (see Daugeliene AH, Filippov V.V. Immune status and ways of its correction in the worm farm animals. M: Agropromizdat).

Aqueous solutions of methycellulose have a high binding, thickening, gelling ability. Non-toxic, resistant to various chemical agents, physiologically inert, possess biological stability (see WWW.Usolieximprom.ru).

The essence of cooking anthelminthic drug for the treatment of small cattle is as follows.

Sorbic acid is used as preservative in food and medical industries.

Prepare a solution of methylcellulose-100 4% (MC-100). For this purpose, a measured amount of distilled water and heated to 50-60C, then pour it weighed quantity MC-100 and stirred for uniform wetting, leave to swell for 5-10 minutes, then placed in the fridge, which was incubated for 30-35 minutes until a homogeneous gel.

Prepare a tincture of Echinacea 40%. To do this, take a weighed quantity of the herb Echinacea 200 wt.%, pour 40% ethyl alcohol to 1 liter and insist in a dark place for 10 days.

The container is placed albendazole in the amount of 2.5-5.0 wt.%, prolivayuschaya Echinacea 40%reduction in the number of 9-12 wt.%, grind until a homogeneous pasty mass, add a solution of MC-100 4%, while simultaneously continuing the kneading mass, add sorbic acid in quantities of 0.5-1.0 wt.%, then the resulting thick suspension is diluted with constant stirring, the remaining amount of distilled water to 100 wt.%.

EXAMPLES of RECEIVING DEWORMING MEDICATION FOR the TREATMENT of SMALL CATTLE

EXAMPLE 1. To receive anthelminthic drug solution prepared MC-100 0.5%, for this purpose, a measured amount of water 950 wt.% distilled is heated to 50-60C. Then pour it weighed quantity MC-100 0.5% and stirred for uniform wetting. Leave to swell for 5-10 minutes, then placed in the fridge, which was incubated for 30-35 minutes until a homogeneous gel.

Prepare a tincture of Echinacea 40%. To do this, take a weighed quantity of the herbs Echinacea, for example, 200 wt.%, pour 40% ethyl alcohol to 1 liter and insist in a dark place for 10 days.

The container is placed albendazole in the amount of 2.0 wt.%, poured a tincture of Echinacea 40%reduction in the amount of 0.8 wt.%, grind until a homogeneous pasty mass, add a solution of MC-100 0.5%in the amount of 2.0 wt.%. Then while rubbing mass add sorbic acid to the number of 0.3 wt.%. The resulting thick suspension is diluted with constant stirring, the remaining amount of distilled water to 100 wt.%.

Received antihelminthic drug proved to be unstable, because there was a loss of active substance in the sediment, after shaking a uniform consistency was maintained for 5-7 minutes, on the bottom of the tank was observed suspended in a light grey color.

EXAMPLE 2. Carried out analogously to example 1, but prepare a solution MC-100 4%, the ratio of components, wt.% take the following:

Albendazole2,5
Tincture of Echinacea 40%9
The solution MC-100 4%20
Sorbic acid0,5
Distilled water68

Received antihelminthic drug was stable for a long time 10-20 hours, the emulsion is homogeneous over the entire capacity was observed uniform distribution of suspended matter light gray, light viscous consistency.

EXAMPLE 3. Carried out analogously to example 1, but prepare a solution MC-100 4%, while the ratio of the components in the AC.% take the following:

Albendazole5,0
Tincture of Echinacea 40%12
The solution MC-100 4%25
Sorbic acid1,0
Distilled water57

Received antihelminthic drug was stable for a long time 10-20 hours, the emulsion is homogeneous over the entire capacity was observed uniform distribution of suspended matter light gray, fine texture.

EXAMPLE 4. Carried out analogously to example 1, but prepare a solution MC-100 5%, the ratio of components, wt.% take the following:

Albendazole5,0
Tincture of Echinacea 40%12
The solution MC-100 5%25
Sorbic acid1,0
Distilled water57

Received antihelminthic drug was the condition is stable, for a long time 10-20 hours, the emulsion is homogeneous, but the physical properties are not different from examples 2 and 3, but in this example there is overspending MC-100, Echinacea, sorbic acid.

Thus, the most optimal is an anthelmintic drug in examples 2-3.

The TEST RESULTS ANTHELMINTHIC DRUG

FOR the treatment of SMALL CATTLE

Conducted a series of experiments to study the toxicity of 5% suspension of albendazole on MC with the addition of immunostimulant. The first experiment was conducted on 15 nonlinear white mice (males weighing 17-24 g), which once orally introduced a 5% suspension of albendazole at a dose of 740 mg/kg of body weight. The studies found that within 7 days after the injection, there was no single death. The status of the mice during the whole observation time remained satisfactory.

Thus, based on the results of the experience that LD50(Lethal dose 50 is the dose of a substance that causes the death of half of the animals) for a 5% suspension of albendazole oral way of introducing the nonlinear white mice exceeds 740 mg/kg

In the second series of experiments on 30 nonlinear white mice average weight 21-22 g studies of acute toxicity with the introduction of a 5% suspension of albendazole in increasing the dose of the, starting with a dose of 740 mg/kg of body weight (table 1). Animals before the experiment was maintained on the starvation diet for 18 hours. All mice were divided into 5 groups of 6 animals each. White mice of the first group via a stomach tube introduced the drug in a dose of 0.5 ml; the second group - in 1.0 ml; the third group 1.5 ml; animals of the fourth group received 1.0 ml twice, with an interval of 1.5 hours and the fifth group 1.5 ml twice, with an interval of 1.5 hours.

The definition of LD50was performed according to the formula

E - the sum of the products ZD;

Z is the spacing between adjacent doses;

D - arithmetic average of the number of animals, which saw the presence of death under the influence of every two adjacent doses;

n is the number of animals in the group;

LD100the dose that causes death in all animals in the group.

By using the method of Cerberus, the results of the experiment are calculated LD50.

Table 1
Determination of acute toxicity of 5% suspension of albendazole with tincture of Echinacea
Dose, mg/kg7401850370055507400
Survived63210
Palo03456
Z1.53.54.55.5
D1110185018501850
ZD16656475832510175

In the experience of LD50was 2960 mg/kg of body weight of the mouse. Therefore, a 5% suspension of albendazole with immunostimulant refers to toxic substances (IV class of danger)

The study of the anthelmintic efficacy of new dosage forms

Together with Pyatigorsk the state pharmaceutical Academy prepared suspension on MC with the addition of immunostimulant.

The purpose of this study was to investigate anthelmintic efficacy of albendazole suspension. To experience matched 32 of the head of small cattle, spontaneously infested main parasitic infection of the gastrointestinal tract. According to the principle analogues animals were divided into 4 groups of 8 animals each. During experiment the animals were housed under identical conditions.

The first group of animals received valbazen at a dose of 7.5 mg/kg, the second group received a suspension albendazole at a dose of 7.5 mg/kg, the third group received a suspension albendazole at a dose of 10.0 mg/kg, and the fourth group - the suspension of albendazole at a dose of 15.0 mg/kg

Intensifications (IE%) - the ratio of the average number of destroyed or released parasites Ny to the average number of pre-processing Nu, expressed in percent, and Extendedrequest (EE%) - the ratio of the number of fully liberated from infestations of animals x1among the treated animals in group x2multiplied by 100%, determined by coprological studies within 10 days after giving the drug.

The results are presented in table 2.

Dose mg/ kg of LW
Table 2
Anthelmintic activity of medicinal forms of albendazole in sheep (n=120)
DrugsIntens/extense efficiency in % against
StrongestThe dicroceliumsMoniezia
Valbazen7,598,4/87,570,3/45-
Suspension albendazole on MC + immunostimulant7,5100/10063,0/20-
10,0100/10079,0/50100/100
15,0100/100100/100100/100

Analysis studies have shown that suspension of albendazole in therapeutic doses has a high degree of efficiency when the main parasitic infection of the gastrointestinal tract.

The present invention in comparison with the prototype and other known technical solution has the following advantages:

- high degree of effectiveness;

- easy technologists prepare;

firmness of the suspension;

environmental be the danger;

- immune-stimulating properties;

the cost of the suspension below the proposed standard.

- refers to low-toxic compounds (IV class of danger).

Antihelminthic drug for the treatment of small cattle, including albendazole and distilled water, characterized in that it additionally contains the tincture of Echinacea 40%solution of methylcellulose-100 4%and sorbic acid in the following ratio, wt.%:

Albendazole2,5-5,0
Tincture of Echinacea 40%9-12
The solution of methylcellulose-100 4%20-25
Sorbic acid0,5-1,0
Distilled waterrest



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a new derivative of sulfonamide substituted imidazoquinolines, and specifically to N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo-[4,5-c]-qunolin-1-yl]-1,1-dimethylethyl}-methanesulfonamide and its pharmaceutically acceptable salts, as well as to a pharmaceutical composition based on this compound.

EFFECT: invention also relates to a method of inducing biosynthesis of cytokines in an animal organism and methods of treating viral and oncological diseases in animals using said compound and pharmaceutical composition based on said compound.

5 cl, 1 tbl, 39 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology and design of agents with immunomodulating properties. A new fungal strain Penicillium verrucosum VKPM F-984 and a new immunomodulating agent based on the strain are proposed. The strain is extracted from microflora of ginseng roots and is kept in a medium which contains mineral salts, glucose and asparagine. Fungus mycelium is extracted with a water-alcohol solution (70% ethanol solution). The advantage of this agent is its natural occurrence and effecient stimulation of adaptive capabilities of the body.

EFFECT: obtaining an extract which has stimulating action on cell and humoral immunity, improves immune status of the body.

3 cl, 2 ex

FIELD: chemistry.

SUBSTANCE: in formulas (I) and (Ia) . A is 1-cyclopentene-1,2-diyl; Z1 and Z2 are O; E is phenyl substituted with 1-4 substituting groups selected from halogen, Y is phenyl substituted with 1-2 substituting groups selected from halogen, C1-C6alcoxy, halogen C1-C6alcoxy; the meaning of other radicals are indicated in the formula of the invention. The invention refers also to the pharmaceutical composition including the compound of the invention, to the application of the said compound at preparation of the medicinal agent and to the application for DHODH inhibition.

EFFECT: compound of the present invention can find application as medicinal agent inhibiting dehydroorotate dehydrogenase.

9 cl, 18 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to occupational diseases, and can be used for correction of immune alterations in persons being in contact with toxic substances. The method is carried out as follows. Introduction of immunostimulant Cyclopheron is preceded with individual adverse effect test by incubation in vitro of Cyclopheron and mononuclear cells separated from peripheral blood. Cyclopheron is introduced provided CD19+ B-lymphocyte count is exceeded by 20% and more, and activated HLA-DR+ lymphocyte count by 15% and more.

EFFECT: method allows improving effectiveness of correction of immune alterations owing to prediction of body's immune response to Cyclopheron therapy.

1 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel diazaindoledicarbonylpiperazinyl compounds of formula I, including its pharmaceutically acceptable salts, which possess antiviral activity and can be used for HIV-infection treatment. In compounds of formula I Q represents , T represents -C(O)- or -CH(CN)-; R1 represents hydrogen; R3 represents hydrogen; R5 is independently selected from group including halogen, cyano, XR9 and B; R2 and R4 are absent; R6 represents hydrogen; -- represents carbon-carbon bond; -Y- is selected from group including , each of R10, R11, R12, R13, R14, R15, R16 and R17 represents H; R18 is selected from group including C(O)-phenyl, isoquinolyl, quinazolyl; D is selected from group including cyano, 5-member heteroaryl containing 3 heteroatoms selected from nitrogen and oxygen; A is selected from group including phenyl, pyridinyl; B is selected from group including -C(O)CH3; piperazinyl; 5-, 6-member heteroaryl containing 1-3 N atoms and possibly O atom; where said heteroaryl optionally is substituted with from one to three similar or different substituents selected from F; F is selected from group including (C1-6)alkyl, phenyl, pyridinyl, COOR26, -COR21, and -CONR24R25; where phenyl is optionally substituted with (C1-6)alkoxy, CF3, or halogen atom; R9, R24, R25 and R26 each is independently selected from group including hydrogen and (C1-6)alkyl; X represents O; R27 represents piperazinyl, N-methylpiperazinyl, or 3-pirazolyl. Invention also relates to pharmaceutical composition.

EFFECT: obtaining compounds and pharmaceutically acceptable salts, which possess antiviral activity and can be used for treatment of HIV infection.

19 cl, 50 dwg, 4 tbl, 43 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely, to surgical stomatology and can be used at treatment of septic wounds of maxillofacial area. For this purpose the 4.16% cycloferon immunomodulator solution, prepared by its dilution with the 0.9% sodium chloride solution is injected into an exudative phase of a septic wound process against complex medicamental treatment in a wound on turundas. In case of the expressed exudation, the cycloferon solution is diluted with the 10% sodium chloride hypertonic solution. Dressings are performed daily. In a proliferative phase of a wound process cycloferon is injected into a wound a kind of 5% liniment, thus dressings are performed in a day. The way allows raising efficiency of complex treatment of patients with the given pathology without system influence on immune system at the expense of local cycloferon immunocorrection taking into account wound process phases.

EFFECT: increase of efficiency of complex treatment of patients with the given pathology without system influence on immune system at the expense of local cycloferon immunocorrection taking into account wound process phases.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely odontology and can be used for treatment of pyoinflammatory diseases of soft tissues of maxillofacial area. The way is carried out as follows. Roncoleukin is administered in the exudative-inflammatory phase of a purulent wound process in the form of a solution with 500000 ME dose of active substance, into a wound preliminary irrigated by means of 10.0 ml of sterile 0.9% sodium chloride, on the turundas, dilluted either with 0.9%, or 10% sodium chloride solution. Thus a bandage from 20% dimexid solution is imposed on periphery of a purulent wound, spending daily dressings. In a proliferative phase - an irrigation of a wound using the Roncoleukin solution is combined with 500000 ME dose of active substance, diluted with 0.9% solution of sodium chloride and salve dressings with preparations on a water-soluble basis; dressings are spent in a day. The way allows normalising indicators of local immunity of a purulent wound and an oral cavity, to strengthen functional activity of phagocytes of a wound, to accelerate purification of wounds from necrotic masses, to optimise terms of occurrence of granulations.

EFFECT: possibility to normalise indicators of local immunity of a purulent wound and an oral cavity, to strengthen functional activity of phagocytes of a wound, to accelerate purification of wounds from necrotic masses, to optimise terms of occurrence of granulations.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, and can be used for treatment of calicivirus intestinal infection at children. For this purpose simultaneously with symptomatic therapy children's anaferon is prescribed perorally. In the first days of disease anaferon is prescribed in a dose of 0.3 g each 30 minutes within 2 hours. Then 3 more tablets of 0.3 g at regular intervals. The next 4 days it is prescribed in a dose of 0.3 g 3 times a day.

EFFECT: reduction of terms of treatment at the expense of stimulation of development of endogenous interferons and activation of process of development of specific antibodies, restoration in short terms of a gastroenteric tract microbiocenosis.

2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to new pyrrolopyrimidinone derivatives with formula (I) and their pharmaceutically used salts, with inhibition properties towards GSK-3, as well as to intermediate compounds with formula (Ic). In compounds with formula (I) and formula (Ic)

A1 is -(CH2)2- or -(CH2)3-; A is a single bond or a group, which links A1 and G1 in form of A1 -C(=O)-G1, A1- (C=O)-O-G1, A1 -(C=O)-NR101-G1, A1-O-(C=O)-G1, A1 -NR104-G1, A1-NR105-(C=O)-G1, A1-NR106-S(=O)2-G1, A1-NR107-(C=O)-O-G1 or A1-NR108-(C=O)-NR109-G1; G1 is a single bond or a bivalent group, which can be obtained through removal of two hydrogen atoms from any alicyclic hydrocarbon with 3-6 carbon atoms, phenylene, monocyclic or cyclic aromatic heterocyclic compound with 2-9 carbon atoms, with 1-2 heteroatoms in a ring, chosen from O or N, or monocyclic heterocyclic compound 2-6 carbon atoms, with 1-2 heteroatoms in a ring, chosen from O or N; A3 is a single bond or bivalent acyclic aliphatic hydrocarbon group with 1-3 carbon atoms, which links G1 with A4 of the same or different carbon atom; A4 is a single bond or a group, which links A3 with G2 in form of A3-C(=0)-G2, A3-C(=0)-0-G2, A3-C(=0)-NR121-G2, A3-O-G2, A3-NR124-G2, A3-NR125-C(=0)G2 or A3-S-G2. Description of other radical is given in the formula of invention.

EFFECT: compounds can be used in treating such diseases as diabetes, neurodegenerative diseases and others.

43 cl, 3 tbl, 513 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, particularly to immunology, and concerns treatment of rheumatoid arthritis associated with inadequate response to TNF-alpha inhibitor. The treatment is ensured by intravenous introduction of antibodies bound with CD20, particularly humanised 2H7v16, containing variable domains presented with SEQ ID Nos. 1 and 2. Antibodies are injected intravenously in dosage 1000 mg twice.

EFFECT: effective treatment of arthritis associated with inadequate response to TNF-alpha inhibitor due to introduction regimen developed by the applicant, extension of range of medical products for treatment of said pathology.

2 cl, 1 tbl, 1 ex

FIELD: pharmacology.

SUBSTANCE: invention concerns organic chemistry and salicylanilide derivative of gross formula C14H10Br2ClNO2, particularly N-(3-chloro-4-methylphenyl)-3,5-dibromosalicylamide as active component of vermicide medication. Indicated property enables application of claimed compound in medicine and veterinary.

EFFECT: cestodacide, nematodacide effect, efficient fascioliasis treatment.

1 cl, 5 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: treating of the patients with chronic opisthorchiasisis ensured by choleretic therapy, general health-improving procedures and therapeutic diet. Intake of choleretic and anthelmintic agents is combined with exposure of a physical agent on the hepatic region. A choleretic phyto tea is followed with a magnetic preparation Ekorsol dosed 3 teaspoons 3 times a day after meal during seven days. Simultaneously the gall bladder region is exposed to the travelling pulse magnetic field involving paravertebral T11-T12 by locally-segmental technique during 15 minutes, twice a day for therapeutic course 10 days.

EFFECT: due to selected magnetotherapy regimen, the method provides microcirculation improvement, decrease in free radicals and stimulation of regenerative and reparative processes in tissues, and remission prolongation, reduction of early recurrences, decrease in complications associated with dyskinetic biliary excretion disorders.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: complex agent for treatment and prevention of gastrointestinal helminths in domestic carnivores contains anthelmintic Phenasal, Nilverm and a base - phosphogypsum and calcium carbonate in the ratio as follows, wt %: Nilverm - 0.6-1.0; Phenasal - 3.6-4.4; phosphogypsum - 60.0-65.0; calcium carbonate - the rest.

EFFECT: more effective dehelmintisation with lower toxicity of the preparation.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: composition contains a compound of avermectine group, Praziquantel, Levamisole and a desired additive that is mixed Dimedrol, dimethyl sulphoxide, dimethyl formamide and benzyl alcohol in weight ratio 1:35-40:8-12:30-35 respectively, in certain component ratio. Said compound of avermectine group is either Ivermectine, or Abamectine, or Doramectine, or Moxydectine.

EFFECT: improved clinical effectiveness with regard to helminthiasis in animals.

2 cl, 2 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: dry aqueous extract from aerial scabiose centaury (Centaurea scabiosa L.) is applied as an antiopisthorchosis agent. The method for making said preparation involves extraction of aerial scabiose centaury (Centaurea scabiosa L.) with purified water under certain conditions.

EFFECT: effective antiopisthorchotic action.

2 cl, 5 tbl, 15 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science and concerns treatment of helminthic invasions ensured by introduction into gastrointestinal tract of a dog, a cat, or a pig of vegetable-oil agent prepared as follows: in a dark-glass pot containing corn oil 800.0 g (85.2 wt %), under stirring powdered dry plants are added including horse gowan blossom 20.0 g (2.1 wt %), peppermint leaves, blossom and stems 20.0 g (2.1 wt %), common plantain leaves 20.0 g (2.1 wt %), ginger plant inflorescences 15.0 g (1.6 wt %), vitamin pumpkin seed 30.0 g (3.2 wt %), common thyme leaves and stems 20.0 g (2.1 wt %), ground shield-roots rhizome 15.0 g (1.6 wt %). The mixture is drawn under stirring within 20-25 days. Further, oily infusion is separated. Per each 100 g thereof, sea-buckthorn oil 6.0 g (6 wt %) and formalin 0.6 g (0.6 wt %) are added. The agent is given to animals within five-six days before forage and water in dose 0.2-1.0 ml/kg of body weight on end.

EFFECT: method provides integrated anthelmintic and antiinflammatory, wound healing action on gastrointestinal mucosa of animals without by-effects.

FIELD: medicine; surgery.

SUBSTANCE: patient is subjected to transdermal cyst draining, aspiration of its content, scolicidal processing of cavity and removal of cyst chitin coat, transdermal cyst draining being performed through 3-4 cm of healthy liver parenchima. After aspiration of cyst content into its cavity in volume equal to 1/4-1/3 of volume of removed echinococcal liquid, scolicidal preparation is introduced. Scolicidal preparation is replaced 1 time in 24 hours during first two days. When scolicidal processing is finished chitin coat of cyst is removed. For this purpose 2-3 times at day time for 1-2 hours with 2-4 hour breaks 1% water solution of sodium hypochloride in volume equal to 1/4-1/3 of volume of removed echinococcal liquid is introduced into cyst cavity. Before each replacement of solution cyst cavity is washed with 1% water solution of sodium hypochloride. At night time and during breaks between washings external passive draining is carried out. Procedure of chitin coat removal is carried out during 7-10 days and is finished after complete stop of its fragments discharge. After that during 5-7 days 1-2 times a day sanation of remaining cavity is carried out with 10-15 ml of antiseptic solution.

EFFECT: elimination of radiation loading on patient and operator, reduction of traumaticity and treatment terms, reduction of number of complications and liver echinococcosis recurrences.

1 ex

FIELD: medicine; pharmacology.

SUBSTANCE: pharmaceutical composition includes an anthelminthic agent chosen from the group, consisting of macroleads, benzimidazoles, isoquinolones, pyrantel or their mixes, and the first inert material, masking taste. The inert material has porous structure with an internal surface approximately of 500-1500 m2/g and the surface area according to VET is approximately 5000 m2/g. As an inert material, usually use charcoal.

EFFECT: improved masking of taste and the prolonged liberation of the anthelminthic agent.

16 cl, 1 dwg

FIELD: medicine; dermatovenereology.

SUBSTANCE: in steady process stage in the first days of treatment Prasiquantel is introduced in single dose 20 mg/kg in the afternoon. Next days additionally biologically active food additive "Progelvit" is introduced in dosage 1 dessert spoon 2 times a day with meal within 14 days. 7 days later additionally food additive "Progelvit" is introduced in dosage 1 dessert spoon 2 times a day with meal within 14 days.

EFFECT: effective treatment at reduced number of complications due to considerable decrease in dose of Prasiquantel.

1 ex

FIELD: medicine.

SUBSTANCE: dehelmintisation follows nycodine therapy dosed 0.5 g 3 times a day before meal within 14 days. Dehelmintisation is provided by biologically active food additive "Progelvit" dosed 1 dessertspoon 2 times a day during meal within 14 days. Then phlamine is dosed 0.05 g 3 times a day 30 minutes before meal within 14 days. 7 days after therapy course is repeated including biologically active food additive "Progelvit" dosed 1 dessertspoon 2 times a day during meal within 14 days.

EFFECT: method provides decrease in complications number caused by high-effective dehelmintisation.

1 ex

FIELD: medicine.

SUBSTANCE: invention describes application of compound which has formula or its salt for prevention or reduction of biofilm formation on abiotic surface or for prevention or reduction of viable microbes growth on abiotic surface, where R1 represents straight or branched alkyl group containing from 8 to 16 carbon atoms in the 2-nd or 3-d position of morpholene ring and R2 represents straight or branched alkyl group containing from 2 to 10 carbon atoms substituted with hydroxy group, except in alfa-position, sum of carbon atoms in groups R1 and R2 constituting at least 10 and preferably 20. Abiotic surface is a medical device, device for fluid medium storage, device of fluid storage delivery or surgical instrument.

EFFECT: invention ensures non-viability of any bacterial biofilm.

20 cl, 3 tbl, 1 ex

Up!